A rare disease should not mean a life without possibilities.
Advancing care through innovation
At Cereno Scientific, we are developing novel therapies with disease-modifying potential and favorable safety and tolerability for people living with rare cardiovascular and pulmonary diseases.
Our vision is clear:
To enhance and extend life by bringing new treatments to those affected by serious rare heart and lung diseases.
Behind every therapy we develop is a deep understanding that each data point represents a person, someone living with limitations, uncertainty, and the need for better options.
Our Focus – Rare Cardiovascular and Pulmonary Diseases
Addressing high unmet medical needs
Our research focuses on rare diseases in which the heart, lungs, and blood vessels are under strain due to abnormal pressure, scarring, or inflammation.
Today, treatment options are limited, often manage symptoms and not the root cause of the disease. Cereno’s approach aims to go deeper by targeting the underlying mechanisms of disease to create therapies that could offer long-term benefit and improved quality of life.
Our Development Programs
CS1 – Pulmonary Arterial Hypertension (PAH)
A potential new oral treatment designed to act on the root causes of PAH with encouraging early data suggesting improvement in lung vessel structure and right heart function. CS1 has received Fast Track designation from the the FDA, highlighting its potential to address this serious condition.
CS014 – Pulmonary Hypertension – Interstitial Lung Disease (PH-ILD)
A next-generation therapy candidate being developed for PH-ILD, a progressive lung disease. CS014 has shown favorable safety and tolerability in a Phase I trial and could represent a new way to slow or alter the disease process.
CS585 – Novel Prostacyclin Receptor Agonist
In early research, CS585 has shown potential to prevent blood clots without increasing bleeding risk, which could be valuable in rare thrombotic disorders.
Participating in Clinical Research
Our commitment to ethical and transparent studies
Cereno conducts all clinical trials according to international ethical and regulatory standards.
We collaborate closely with physicians, research centers, and regulatory agencies to ensure patient safety and data integrity at every stage.
Cereno Scientific does currently not have an ongoing clinical trial. A clinical trial for patients with PAH is planned to start in the second quarter of 2026 in the US, Europe and South America. A clinical trial for patients with PH-ILD is planned to start in the first quarter of 2027. More information will be shared as available.
We encourage patients to discuss trial participation with their healthcare providers to determine what may be suitable for them.
Living with Rare Diseases
You are not alone
While we do not provide medical advice or treatment through this website, we recognize the importance of patient organizations and support networks.
We actively engage with the rare disease community to learn from patients’ experiences and ensure that their perspectives inform our development work.
Good resources can be found through organizations such as:
PHA Europe & Global
PH Association (US-focused)
PH Aware
AfPH
Looking ahead
Hope through science
Our ongoing research reflects a long-term commitment: to bring forward safe, effective, and meaningful treatments for patients who today have few options.